Imovax Polio

Poliovirus (Inactivated) Type 3 (Saukett Strain), Poliovirus (Inactivated) Type 2 (Mef-1 Strain) and Poliovirus (Inactivated) Type 1 (Mahoney Strain), the active ingredient in Imovax Polio, is an antiviral vaccine presented as an injectable solution for intramuscular or subcutaneous administration. It induces active immunity and is used to prevent poliomyelitis caused by poliovirus types 1, 2 and 3 in children and adults at risk.

GNH USA supplies Imovax Polio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and health‑care providers throughout worldwide.

Imovax Polio is an inactivated polio vaccine used to prevent poliomyelitis, a viral infection of the nervous system. - Poliomyelitis (type 1): Provides immunity against type 1 poliovirus. - Poliomyelitis (type 2): Provides immunity against type 2 poliovirus. - Poliomyelitis (type 3): Provides immunity against type 3 poliovirus.

Common Side Effects: - Injection site pain, redness or swelling. - Low‑grade fever. - Headache. - Fatigue. - Nausea. - Muscle aches.

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions. - Guillain‑Barré syndrome. - Seizures. - Persistent high fever. - Severe hypotension. - Neurological complications such as encephalitis.

Before vaccination, consider the following precautions: - Allergy screening: Verify no severe hypersensitivity to vaccine components. - Acute illness: Defer administration in persons with moderate or severe fever. - Observation: Monitor the patient for at least 15 minutes after injection. - Immunocompromised status: Counsel that immune response may be reduced. - Pregnancy and lactation: Discuss potential risks with a healthcare professional; safety data are limited. - Store at 2‑8 °C: Keep refrigerated, protect from light, do not freeze or shake.

Imovax Polio may interact with other agents as follows: Major Interactions (Avoid): - Live attenuated vaccines administered concurrently: May interfere with immune response. - Immunoglobulin therapy given within 4 weeks: Can reduce vaccine efficacy. Moderate Interactions (Monitor Closely): - Immunosuppressive therapy: May diminish antibody production. - Chronic corticosteroid use: May lower immunogenicity. - Underlying immunodeficiency: May affect vaccine response. - Recent blood product transfusion: May alter antibody development.